The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions

The U.S. federal government provides two tracks for eligible patients to obtain access outside clinical trials to investigational interventions currently under study for potential clinical benefits: the Food and Drug Administration’s expanded access pathway and the pathway created by the more recent...

Полное описание

Сохранить в:  
Библиографические подробности
Главные авторы: Spector-Bagdady, Kayte (Автор) ; Weatherwax, Kevin J. (Автор) ; Gravelin, Misty (Автор) ; Shuman, Andrew G. (Автор)
Формат: Электронный ресурс Статья
Язык:Английский
Проверить наличие: HBZ Gateway
Interlibrary Loan:Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany)
Опубликовано: 2019
В: The Hastings Center report
Год: 2019, Том: 49, Выпуск: 2, Страницы: 36-39
Online-ссылка: Presumably Free Access
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000naa a22000002c 4500
001 1937529576
003 DE-627
005 20251002055614.0
007 cr uuu---uuuuu
008 251002s2019 xx |||||o 00| ||eng c
024 7 |a 10.1002/hast.991  |2 doi 
035 |a (DE-627)1937529576 
035 |a (DE-599)KXP1937529576 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Spector-Bagdady, Kayte  |e VerfasserIn  |4 aut 
109 |a Spector-Bagdady, Kayte  |a Bagdady, Kayte Spector- 
245 1 4 |a The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions 
264 1 |c 2019 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a The U.S. federal government provides two tracks for eligible patients to obtain access outside clinical trials to investigational interventions currently under study for potential clinical benefits: the Food and Drug Administration’s expanded access pathway and the pathway created by the more recent Right to Try Act. In this issue of the Hastings Center Report, with a critical focus on patients, industry, and the research enterprise, Kelly Folkers and colleagues frame the inherent challenges that these pathways are meant to solve and have also inadvertently created. But an additional key focus is how the relevant situations should be managed at the bedside and how the system risks both inefficient and inequitable access to options at the institutional level. Although either pathway could be helpful to patients, the challenges of having the pathways coexist are greater than the sum of their parts. Individual clinicians represent the front line of the regulatory and eligibility challenges of expanded access and right to try, making clinical education a critical component of a comprehensive approach to using them well. But it is medical institutions that must take the lead on supporting access to investigational options in the most equitable and effective manner possible. 
601 |a Institution 
601 |a Intervention 
700 1 |a Weatherwax, Kevin J.  |e VerfasserIn  |4 aut 
700 1 |a Gravelin, Misty  |e VerfasserIn  |4 aut 
700 1 |a Shuman, Andrew G.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a Hastings Center  |t The Hastings Center report  |d Malden, Mass. : Wiley, 1971  |g 49(2019), 2, Seite 36-39  |h Online-Ressource  |w (DE-627)341346551  |w (DE-600)2067369-3  |w (DE-576)258761822  |x 1552-146X  |7 nnas 
773 1 8 |g volume:49  |g year:2019  |g number:2  |g pages:36-39 
856 |u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hast.991  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h publisher [deprecated] 
856 4 0 |u https://doi.org/10.1002/hast.991  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.991  |x Verlag  |z lizenzpflichtig  |3 Volltext 
912 |a NOMM 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4779655757 
LOK |0 003 DE-627 
LOK |0 004 1937529576 
LOK |0 005 20251002055614 
LOK |0 008 251002||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2025-09-26#66FC908048F7E0218EB18E55C941C55FA3EE384C 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixrk  |a ixzs  |a zota  |a tiep 
OAS |a 1 
ORI |a TA-MARC-ixtheoa001.raw